



SC  
JP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

ANDERSON and GALIBERT

Serial No: 09/705,985

Filed: November 3, 2000

For: METHOD OF INHIBITING OSTEOCLAST ACTIVITY

Docket No.: 2874-B

Confirmation No. 6890

Group Art Unit: 1646

Examiner: N. Basi

**RESPONSE TO RESTRICTION REQUIREMENT and  
THIRD PRELIMINARY AMENDMENT**

RECEIVED

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

JUL 3 2002  
TECH CENTER 1600/2900

**Response to Restriction Requirement**

In response to the Restriction Requirement mailed March 26, 2002, the applicants hereby without traverse elect Group III, which includes claims 5-16, 18-20 and 22-24 to the extent that they encompass a method of ameliorating the effects of excess bone loss comprising administering RANK polypeptide of SEQ ID NO:2.

**Third Preliminary Amendment**

Prior to examining the aforementioned patent application on its merits, applicants request that the following amendments be entered into the application:

**In the Specification:**

Please substitute the paper copy of the Sequence Listing submitted herewith for the Sequence Listing that was filed previously on November 3, 2000.

Please delete in its entirety the paragraph located at page 4, line 37, to page 5, line 5 and substitute therefor the following paragraph:

-- The biological activity of RANK analogs or muteins can be determined by testing the ability of the analogs or muteins to bind human RANKL (SEQ ID NOS:7 and 8), for example as described in the Examples herein. Suitable assays include, for example, an enzyme immunoassay or a dot blot, and assays that employ cells expressing RANKL. Suitable assays also include, for example, inhibition assays, wherein soluble